Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + amoxicillin + levofloxacin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A triple therapy combination used primarily as a second-line treatment for Helicobacter pylori infection after failure of standard first-line therapies. This regimen combines esomeprazole (a proton pump inhibitor) with amoxicillin (a penicillin-class antibiotic) and levofloxacin (a fluoroquinolone antibiotic). The combination works by suppressing gastric acid production while delivering dual antibiotic coverage against H. pylori.
- Brand names
- Esovit Kit
- Other names
- EAL therapyEAL regimen
02
Targets
PBP (Penicillin-binding protein family)DNA gyraseATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on esomeprazole + amoxicillin + levofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + amoxicillin + levofloxacin.